Randomized Double Blind Placebo-controlled Clinical Safety, Tolerability and Pharmacokinetic/-Dynamic Study on the Effects of Escalating Single Intravenous Doses of EA-230 on the Innate Immune Response During Experimental Human Endotoxemia

Trial Profile

Randomized Double Blind Placebo-controlled Clinical Safety, Tolerability and Pharmacokinetic/-Dynamic Study on the Effects of Escalating Single Intravenous Doses of EA-230 on the Innate Immune Response During Experimental Human Endotoxemia

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2016

At a glance

  • Drugs EA 230 (Primary)
  • Indications Renal failure
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Exponential Biotherapies
  • Most Recent Events

    • 22 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 11 Dec 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 28 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top